Summary
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Official Title
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Keywords
Hepatitis B, Chronic, Hepatitis B Virus, Chronic Hepatitis B, HBV, Hepatitis, Hepatitis A, Hepatitis B, Virus Diseases, Herpesviridae Infections, Chronic Hepatitis, VIR-2218, VIR-3434, PEG-IFNα, VIR-2218 + VIR-3434, VIR-2218 + VIR-3434 + PEG-IFNα, VIR-2218 + PEG-IFNα, VIR-3434 + PEG-IFNα